Associazione Nazionale Medici Cardiologi Ospedalieri

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Survey sull’utilizzo della terapia con SGLT2i: caratteristiche cliniche e terapeutiche dei pazienti affetti da scompenso cardiaco in un gruppo di centri di Puglia, Molise ed Abruzzo. A Cura dell’AREA ANMCO CArdio REno MEtabolica
Anno:
2023
Negli ultimi anni il trattamento farmacologico dello scompenso cardiaco a frazione di eiezione ridotta ha subito un notevole sviluppo. Gli inibitori del co-trasportatore sodio–glucosio tipo 2 rappresentano la più recente classe di farmaci che ha dimostrato di ridurre i ricoveri ospedalieri per scompenso e i decessi per cause cardiovascolari…
Sacubitril/valsartan improves exercise performance in patients with heart failure: a dose-dependent effect
Anno:
2023
Background: Sacubitril/Valsartan therapy has become a cornerstone of heart failure with reduced ejection fraction (HFrEF) pharmacological therapy due to its positive prognostic impact. However, conflicting results have emerged on the effects of sacubitril/valsartan on exercise performance assessed by cardiopulmonary exercise test (CPET). Aim of the study: The aim of…
CARATTERISTICHE CLINICHE E TERAPEUTICHE DEI PAZIENTI AFFETTI DA SCOMPENSO CARDIACO IN TERAPIA CON SGLT2I AFFERITI IN AMBULATORIO DELLO SCOMPENSO
Anno:
2023
Gli inibitori del co–trasportatore sodio–glucosio tipo 2 rappresentano la più recente classe di farmaci che ha dimostrato di ridurre i ricoveri ospedalieri per scompenso e i decessi per cause cardiovascolari nei pazienti affetti da scompenso cardiaco a frazione di eiezione ridotta e sono di fatto entrati immediatamente nelle più…
Berberine associated to Dapagliflozin exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-bloking agent Trastuzumab through pAMPK activation and reduction in Interleukin-6 levels
Anno:
2023
Background: Trastuzumab has improved the prognosis in patients with HER2-positive breast cancer, but it can induce left ventricular dysfunction with reduced ejection fraction or HF during treatment. Dapagliflozin is a SGLT2i with cardio-renal benefits. In the DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial, the sodium-glucose cotransporter…
Up to 12 month trends in clinical and biochemical parameters after SGLT2i therapy in patients affected by heart failure patients with reduced ejection fraction
Anno:
2023
Background. The type-2 sodium-glucose cotransporters inhibitors (SGLT2i) are a new relevant therapeutic option for patients affected by chronic heart failure with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the effects of SGLT2i on some clinical and biochemical parameters as well as the persistence of…
Clinical characteristics of patients affected by heart failure patients with reduced ejection fraction and undergoing SGLT2i therapy
Anno:
2023
Background. The type-2 sodium-glucose cotransporters inhibitors (SGLT2i) are a new relevant therapeutic option for patients affected by chronic heart failure with reduced ejection fraction (HFrEF). The aim of this study was to evaluate the clinical characteristics and therapy of HFrEF patients undergoing SGLT2i therapy. Methods. We evaluated the consecutive…